This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hughes, O. D. M. Articles by Schubiger, P. A. Search for Related Content PubMed PubMed Citation Articles by Hughes, O. D. M. Articles by Schubiger, P. A.

Targeting Superficial Bladder Cancer by the Intravesical Administration of Copper-67–Labeled Anti-MUC1 Mucin Monoclonal Antibody C595

From the Departments of Urology and Pathology, City Hospital; Departments of Medical Physics and Radiology, University Hospital; and Cancer Research Laboratory, School of Pharmaceutical Sciences, University of Nottingham, Nottingham, United Kingdom; and Centre for Radiopharmaceutical Sciences, Paul Scherrer Institute, Villigen, Switzerland.

Address reprint requests to Prof A.C. Perkins, Department of Medical Physics, University Hospital, Nottingham NG7 2UH, United Kingdom; email alan.perkins{at}nottingham.ac.uk

PURPOSE: More effective intravesical agents are required to limit the recurrence and progression of superficial bladder cancer. This study assessed the ability of copper-67 (⁶⁷Cu)-C595 murine antimucin monoclonal antibody to bind selectively to superficial bladder tumors when administered intravesically, with a view to its development for therapy.

PATIENTS AND METHODS: Approximately 20 MBq of ⁶⁷Cu-C595 monoclonal antibody was administered intravesically to 16 patients with a clinical indication of superficial bladder cancer. After 1 hour, the bladder was drained and irrigated. Tissue uptake was assessed by imaging and by the assay of tumor and normal tissues obtained by endoscopic resection.

RESULTS: Tumor was correctly identified in the images of 12 of 15 patients who were subsequently found to have tumors. Assay of biopsy samples at 2 hours showed a mean tumor uptake of 59.4% of the injected dose per kilogram (SD = 48.0), with a tumor-to-normal tissue ratio of 14.6:1 (SD = 20). After 24 hours (n = 5), this decreased to 4.3% of the injected dose per kilogram (SD = 2.9), with a tumor-to-normal tissue ratio of 1.8:1 (SD = 0.8).

CONCLUSION: This study indicates a promising method for the treatment of superficial bladder cancer. Although the mean initial tumor uptake was high, effective therapy of bladder tumors will require an increased retention of the cytotoxic radionuclide in tumor tissue.

This article has been cited by other articles:

				V. B. Wreesmann, E. M. Sieczka, N. D. Socci, M. Hezel, T. J. Belbin, G. Childs, S. G. Patel, K. N. Patel, G. Tallini, M. Prystowsky, et al. Genome-Wide Profiling of Papillary Thyroid Cancer Identifies MUC1 as an Independent Prognostic Marker Cancer Res., June 1, 2004; 64(11): 3780 - 3789. [Abstract] [Full Text] [PDF]

				D. M. Goldenberg Targeted Therapy of Cancer with Radiolabeled Antibodies J. Nucl. Med., May 1, 2002; 43(5): 693 - 713. [Abstract] [Full Text] [PDF]

				N. Amara, G. S. Palapattu, M. Schrage, Z. Gu, G. V. Thomas, F. Dorey, J. Said, and R. E. Reiter Prostate Stem Cell Antigen Is Overexpressed in Human Transitional Cell Carcinoma Cancer Res., June 1, 2001; 61(12): 4660 - 4665. [Abstract] [Full Text] [PDF]

				A. Murray, M. S. Simms, D. P. Scholfield, R. M. Vincent, G. Denton, M. C. Bishop, M. R. Price, and A. C. Perkins Production and Characterization of 188Re-C595 Antibody for Radioimmunotherapy of Transitional Cell Bladder Cancer J. Nucl. Med., May 1, 2001; 42(5): 726 - 732. [Abstract] [Full Text]